<DOC>
	<DOCNO>NCT00656136</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center Phase IIb/III trial perform patient NSCLC receive previous treatment least one two line cytotoxic chemotherapy ( one line must platinum-containing regimen ) either gefitinib erlotinib period least 12 week progress . The primary objective randomize trial determine efficacy BIBW 2992 single agent ( Arm A ) compare match placebo ( Arm B ) patient population . Patients treatment arm receive best supportive care addition study treatment . Patients enrol trial treat follow death lose follow-up .</brief_summary>
	<brief_title>BIBW 2992 BSC Versus Placebo BSC Non-small Cell Lung Cancer Patients Failing Erlotinib Gefitinib ( LUX-LUNG 1 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients pathologic confirmation NSCLC Stage IIIB ( pleural effusion ) Stage IV adenocarcinoma fail least one two line cytotoxic chemotherapy ( include adjuvant chemotherapy ) . One chemotherapy regimens must platinumbased . 2 . Progressive disease follow least 12 week treatment erlotinib ( Tarceva速 ) gefitinib ( Iressa速 ) 3 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance Score 0 , 1 2 4 . Patients least one tumor lesion accurately measure magnetic resonance imaging ( MRI ) , compute tomography ( CT ) least one dimension long diameter record &gt; 20 mm use conventional technique &gt; 10 mm spiral CT scan 5 . Male female patient age &gt; 18 year 6 . Life expectancy least three ( 3 ) month 7 . Written inform consent consistent ICHGCP guideline Exclusion criterion : 1 . Use erlotinib ( Tarceva速 ) gefitinib ( Iressa速 ) within 14 day treatment Day 1 2 . Chemo , hormone ( megestrol acetate steroid require maintenance noncancer therapy ) immunotherapy within past 4 week 3 . Active brain metastasis 4 . Significant recent acute gastrointestinal disorder diarrhea 5 . Patients lifethreatening illness organ system dysfunction , 6 . Other malignancy diagnose within past five ( 5 ) year 7 . Radiotherapy within past 2 week prior treatment 8 . History clinically significant uncontrolled cardiac disease 9 . Adequate ANC platelet count 10 . Adequate liver kidney function 11 . Patients serious active infection include know HIV , active hepatitis B active hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>